Research

A unique vaccine to protect against COVID-19 begins Phase 1 clinical testing in early April at the at the Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center. Scientists developed a nanoparticle vaccine based on a ferritin platform that offers a flexible approach to target multiple variants of SARS-COV-2 and potentially other coronaviruses as well

EIDB is leveraging WRAIR’s ID countermeasure infrastructure and expertise to compress what would be years of discovery and design work into several months

COVID-19

MERS

Hemorrhagic fevers are a family of infectious diseases including Ebola, Marburg, Lassa fever and yellow fever that affect the body’s blood clotting abilities. Recent outbreaks have occurred in militarily strategic regions like West Africa where WRAIR’s research infrastructure has enabled surveillance and countermeasure research.

Ebola

Lassa Fever

Marburg

WRAIR continues to leverage its expertise in flaviviruses to improve solutions for century-old infectious disease threats, like yellow fever, and to innovate new products to combat new and re-emerging pathogens like Zika virus.

Tick-borne Encephalitis

Yellow Fever

Zika

Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins

A Forward-Thinking Approach to Coronaviruses

Advancing Countermeasures Against Hemorrhagic Fevers

Flavivirus Threats Persist